List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 23 studies with search of: "myotonic dystrophy" OR "Myotonic Dystrophy"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
Conditions: Myotonic Dystrophy;   Sudden Cardiac Death
Interventions: Procedure: Electrophysiological study;   Device: pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant
2 Completed Efficacy and Safety of DHEA for Myotonic Dystrophy
Condition: Myotonic Dystrophy
Intervention: Drug: dehydroepiandrosterone 100 and 400 mg
3 Recruiting Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Conditions: Myotonic Dystrophy;   Muscular Dystrophy, Facioscapulohumeral;   Muscular Dystrophy
Intervention:
4 Active, not recruiting Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Intervention: Drug: SomatoKine/IPLEX
5 Active, not recruiting Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: rhIGF-I/rhIGFBP-3;   Drug: placebo
6 Recruiting A Study of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Condition: Metastatic Breast Cancer
Interventions: Drug: pertuzumab;   Drug: trastuzumab-MCC-DM1
7 Recruiting Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy
Condition: Myotonia
Intervention: Other: withdrawal of non-invasive ventilation
8 Not yet recruiting A Study of Trastuzumab-MCC-DM1 (T-DM1) in Combination With Docetaxel in Patients With Advanced Breast Cancer
Condition: HER2 Positive Breast Cancer
Interventions: Drug: docetaxel;   Drug: Trastuzumab-MCC-DM1 (T-DM1)
9 Recruiting An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine;   Drug: lapatinib;   Drug: trastuzumab-MCC-DM1
10 Enrolling by invitation An Extension Study of T-DM1 in Patients Previously Treated With TDM-1
Condition: Metastatic Breast Cancer
Intervention: Drug: trastuzumab-MCC-DM1
11 Recruiting A Study of Trastuzumab-MCC-DM1 (T-DM1) in Combination With Pertuzumab Administered to Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: pertuzumab;   Drug: trastuzumab-MCC-DM1
12 Recruiting A Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: paclitaxel;   Drug: pertuzumab;   Drug: trastuzumab-MCC-DM1
13 Recruiting A Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Breast Cancer
Interventions: Drug: docetaxel;   Drug: trastuzumab;   Drug: trastuzumab-MCC-DM1
14 Active, not recruiting A Study of of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: trastuzumab-MCC-DM1
15 Active, not recruiting A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: trastuzumab-MCC-DM1
16 Active, not recruiting A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
Condition: Metastatic Breast Cancer
Intervention: Drug: trastuzumab-MCC-DM1
17 Recruiting A Study of Trastuzumab-MCC-DM1 (TDM-1) and GDC-0941 in Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Condition: Metastatic Breast Cancer
Interventions: Drug: GDC-0941;   Drug: trastuzumab-MCC-DM1
18 Completed Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy
Condition: Muscular Dystrophy
Interventions: Drug: dextrose;   Drug: insulin
19 Completed A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: MLN2704 (DM1 conjugated monoclonal antibody MLN591)
20 Completed MLN2704 in Treating Patients With Progressive Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: MLN2704

Previous Page Studies Shown (1-20) Next Page (21-23)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services